Xeris Biopharma Holdings Inc.
04/23/2026 | Press release | Distributed by Public on 04/23/2026 15:09
Additional Proxy Soliciting Materials (Form DEFA14A)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14A INFORMATION
Proxy Statement Pursuant to Section 14(a) of the
Securities Exchange Act of 1934
(Amendment No. )
|
Filed by the Registrant þ
|
Filed by a Party other than the Registrant ¨
|
|||||||||||||||||||
|
Check the appropriate box:
|
||||||||||||||||||||
|
¨
|
Preliminary Proxy Statement
|
|||||||||||||||||||
|
¨
|
Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
|
|||||||||||||||||||
|
¨
|
Definitive Proxy Statement
|
|||||||||||||||||||
|
þ
|
Definitive Additional Materials
|
|||||||||||||||||||
|
¨
|
Soliciting Material under §240.14a-12
|
|||||||||||||||||||
XERIS BIOPHARMA HOLDINGS, INC.
(Name of Registrant as Specified in its Charter)
(Name of Person(s) Filing Proxy Statement, if other than the Registrant)
|
Payment of Filing Fee (Check the appropriate box):
|
|||||||||||||||||||||||
|
þ
|
No fee required.
|
||||||||||||||||||||||
|
¨
|
Fee previously paid with preliminary materials.
|
||||||||||||||||||||||
|
¨
|
Fee computed on table in exhibit required by Item 25(b) per Securities Exchange Act of 1934 Rules 14a-6(i)(1) and 0-11.
|
||||||||||||||||||||||
Xeris Biopharma Holdings Inc. published this content on April 23, 2026, and is solely responsible for the information contained herein. Distributed via EDGAR on April 23, 2026 at 21:09 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]